Upadacitinib hemihydrate
Specifications
2050057-56-0CAS Number
bis((3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide);hydrateIUPAC Name
C34H40F6N12O3Chemical Formula
778.8 g/molMolecular Weight
Upadacitinib hemihydrate; 2050057-56-0; RINVOQ LQ; NEW4DV02U5; 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo(1,2-a)pyrrolo(2,3-E)pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, hydrate (2:1), (3S,4R)-; 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, hydrate (2:1), (3S,4R)-; RefChem:1100658; Rinvoq; (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate(2:1); Upadacitinib hydrate (JAN); (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate; UPADACITINIB HYDRATE [JAN]; upadacitinib hydrate; Rinvoq (TN); UNII-NEW4DV02U5; Upadacitinib (as hemihydrate); CHEMBL5315119; EBC-134021; UPADACITINIB HEMIHYDRATE [WHO-DD]; (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;hydrate; AC-37935; AS-97188; D11048; H53955; (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate (2:1); 1831899-73-0; bis((3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide);hydrate; rel-(3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate(2:1)Synonyms
Products Containing Upadacitinib hemihydrate
린버크서방정30밀리그램(유파다시티닙반수화물)린버크서방정15밀리그램(유파다시티닙반수화물)RINVOQ 30 MG COMPRIMIDOS DE LIBERACION PROLONGADARINVOQ 45 MG COMPRIMIDOS DE LIBERACION PROLONGADARINVOQ 30 MG COMPRIMIDOS DE LIBERACION PROLONGADARINVOQ 15 MG COMPRIMIDOS DE LIBERACION PROLONGADARINVOQ 45 mg, comprimé à libération prolongéeRINVOQ 30 mg, comprimé à libération prolongéeRINVOQ 15 mg, comprimé à libération prolongéeUpadacitinib hemihydrate CAS:2050057-56-0Upadacitinib hemihydrateUpadacitinib Hemihydrate
Page 1 of 2
Companies Selling Upadacitinib hemihydrate
AD
Abbvie Deutschland GmbH & Co. KGGermanySD
SHIJIAZHUANG DINGMIN PHARMACEUTICAL SCIENCES CO., LTDChinaHH
HANGZHOU HONGQIN PHARMTECH CO.,LTDChinaAH
Anhui Haikang Pharmaceutical Co., Ltd.ChinaWH
Wuxi Hexia Chemical CompanyChinaZH
Zhejiang Huayi Pharmaceutical Co., Ltd.China한국
한국애브비(주)Republic of KoreaBS
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.ChinaJX
Jinan Xinnuo Pharmaceutical Co., LtdChina